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Rationale, aims, and objectives: Time to the occurrence of an event is often studied in
health research. Survival analysis differs from other designs in that follow‐up times for individuals
who do not experience the event by the end of the study (called censored) are accounted for in
the analysis. Cox regression is the standard method for analysing censored data, but the assump-
tions required of these models are easily violated. In this paper, we introduce classification tree
analysis (CTA) as a flexible alternative for modelling censored data. Classification tree analysis
is a “decision‐tree”–like classification model that provides parsimonious, transparent (ie, easy to
visually display and interpret) decision rules that maximize predictive accuracy, derives exact P
values via permutation tests, and evaluates model cross‐generalizability.
Method: Using empirical data, we identify all statistically valid, reproducible, longitudinally
consistent, and cross‐generalizable CTA survival models and then compare their predictive accu-
racy to estimates derived via Cox regression and an unadjusted naïve model. Model performance
is assessed using integrated Brier scores and a comparison between estimated survival curves.
Results: The Cox regression model best predicts average incidence of the outcome over time,
whereas CTA survival models best predict either relatively high, or low, incidence of the outcome
over time.
Conclusions: Classification tree analysis survival models offer many advantages over Cox
regression, such as explicit maximization of predictive accuracy, parsimony, statistical robustness,
and transparency. Therefore, researchers interested in accurate prognoses and clear decision
rules should consider developing models using the CTA‐survival framework.
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Time to the occurrence of an event is often studied in health‐related
research. Typically, the event is survival or, conversely, mortality, over
a given period of observation. However, other events may be used as
the endpoint, such as hospitalization, development of disease, or
reaching a threshold for a physiologic marker.1-3
In survival analysis, data from individuals who do not experience
the event by the end of the study are used in model estimation. Such
individuals' survival times are called censored, indicating that that the
study terminated before the event occurred or that the individual
may have been lost to follow‐up at some point during the study. In
either case, censored survival times are used—along with the survivalwileyonlinelibrary.comtimes of individuals who experienced the event during the course of
the study—to construct the survival analysis model.4
Several regression‐based models are specifically designed to
assess the influence of covariates on survival in the presence of cen-
soring. As with all regression analyses, these methods involve making
assumptions about the data, including that variables are independent
and that data can be modelled using linear combinations of these
variables. Moreover, while these models generally show improved
fit when additional variables are included, there is no good indicator
of when the model is over‐fit.5 Given that health data are rarely
strictly linear, but often exhibit interactions and conditional depen-
dencies, assumptions underlying the validity of these survival models
are easily violated.© 2017 John Wiley & Sons, Ltd./journal/jep 1299
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have been proposed as alternatives for modelling survival data (see,
for example6-10). Machine learning algorithms find the best‐fitting
model through automated processes that search through the data to
detect patterns that may include interactions between variables, as
well as interactions within subsets of variables. This is in contrast to
conventional statistics, where a model is chosen and estimated on
the basis of an a priori hypothesis about the underlying relationship
between the variables, and then statistical tests are performed to
evaluate whether the data satisfy crucial assumptions underlying the
validity of the findings.11 In short, machine learning allows the data
to dictate the form of the model, whereas conventional statistics
attempts to fit the data to an investigator‐specified model.
In this paper, we introduce classification tree analysis (CTA) as a
machine learning alternative to conventional regression‐based
models for analysing survival data. Classification tree analysis is a
“decision‐tree”–like classification model that provides accurate, parsi-
monious decision rules that are easy to visually display and interpret,
while reporting P values derived via permutation tests performed at
each node. This approach is attractive to clinicians using model‐derived
prognostic tools in daily practice and to investigators evaluating the
effectiveness of interventions in which the outcome is the time to
the occurrence of an event.
The paper is organized as follows. Section 2 briefly introduces CTA
and describes the data source and analytic framework used in the
current study. Section 3 reports and compares the findings of the
CTA framework and the Cox semiparametric proportional hazard
model,12 the most widely‐used method for analysing survival data.
Section 4 describes the specific advantages of the CTA framework
for developing risk prediction models compared with regression‐based
survival models and discusses extending this approach to the
evaluation of treatment effects in health care interventions.2 | METHODS
2.1 | A brief introduction to CTA
Classification tree analysis is an optimal discriminant analysis (ODA)
model.13 Optimal discriminant analysis is a machine learning algorithm
used to identify the cutpoint on an ordered attribute (variable), or
assignment rule for a categorical attribute, that optimally discrimi-
nates between two or more classes (eg, outcome categories).14 The
optimal cutpoint is determined by iterating through every value on
the attribute and computing the effect strength for sensitivity (ESS),
which is the mean sensitivity across classes standardized using a 0
to 100% scale on which 0 represents the discriminatory accuracy that
is expected by chance and 100% represents perfect discrimination. By
definition, the maximally accurate predictive model uses the optimal
cutpoint that yields the highest ESS versus all other cutpoints. This
optimal model is subjected to a nonparametric permutation test to
assess the statistical significance of the cutpoint. Finally, the repro-
ducibility and generalizability of the model are assessed using cross‐
validation methods, such as jackknife, bootstrap, or hold‐out analysis,
to determine how well it predicts the outcome in new subjects thatmay differ in their characteristics compared to subjects in the original
sample.15-19
CTA models use one or more attributes to classify a sample of
subjects into two or more subgroups represented as model endpoints
(called “terminal nodes” by alternative decision‐tree methods).
Subgroups are known as “sample strata” because the CTA model
stratifies the sample into subgroups that—when considered with
respect to model attributes—are homogeneous within and heteroge-
neous between strata.19 The hierarchically optimal CTA (HO‐CTA)
algorithm involves chained ODA models in which the initial (“root”)
node represents the attribute achieving the highest ESS value for the
entire sample, and additional nodes yielding greatest ESS are
iteratively added at every step on all model branches.20,21 In contrast,
the enumerated optimal CTA (EO‐CTA) algorithm evaluates all possible
combinations of the first 3 nodes, which dominate the solution.16,22
The most robust globally optimal CTA (GO‐CTA) algorithm explicitly
evaluates all possible solutions (called the descendant family) and
identifies the GO‐CTA model reflecting the best combination of ESS
and parsimony—yielding the highest ESS using the smallest number
of strata.19 The software that implements ODA and CTA models
provides an array of options to control the modelling and validation
process (see Yarnold and Soltysik19 for a comprehensive discussion).2.2 | Data
To demonstrate the use of CTA for survival analysis and to compare
this approach to the standard Cox‐regression model, we use a subset
of data from the Framingham Heart Study, which has been collecting
longitudinal data on residents of Framingham, Massachusetts since
1948, to gain insight into the epidemiology of cardiovascular disease
(CVD) and its risk factors (see Mahmood et al23 for an excellent
historical perspective). We use data that comprise 4699 individuals
free of CVD at their baseline exam and followed for up to 11 688 days
(32 years). The variables include systolic and diastolic blood pressure
(mmHg), age (years), serum cholesterol (mg/100 mL), body mass index
(kg/m2), gender, follow‐up time (days), and an indicator of whether the
individual developed CVD or was otherwise censored. The dataset
was accessed as a supplement to the book “Statistical Modeling
for Biomedical Researchers”24 (http://biostat.mc.vanderbilt.edu/
dupontwd/wddtext/index.html#datasets).2.3 | Analytic approach
Split‐half cross‐validation methodology is used throughout the analytic
process to evaluate model reproducibility and generalizability. This
entails randomly drawing subjects from the full sample and assigning
them into 1 of 2 groups: split‐half 1 (SH1) or split‐half 2 (SH2). Next,
models are generated using SH1 as the training sample, and these
models are used to make out‐of‐sample predictions for subjects in
SH2 (the test or “hold‐out” sample). This process is then repeated after
switching the roles of SH1 (test sample) and SH2 (training sample). By
definition, perfectly reproducible (generalizable) models are identical,
and parallel models are identical except for the values of numerical
cutpoints used on model branches.18,19 Unless otherwise noted, all
models make use of all available follow‐up data.
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implementing the widely used Cox semiparametric proportional haz-
ards model,12 which models the effects of covariates on survival time.
The quantity of interest in Cox regression is the hazard function, which
may be described as the risk that the event will occur for a subject
within an observation (ie, follow‐up) period, given that the subject
did not already have the event. A high hazard function indicates a high
event rate (low survival probability), and conversely, a low hazard
function indicates a low event rate (high survival probability). While
Cox regression requires no assumptions about the distribution of fail-
ure (eg, development of CVD) times, it is assumed that the hazards
between any 2 subjects are proportional over time (hence, the name
proportional hazards regression), with the proportion being a function
of the covariates.4 For the current example, we estimate the time to
the development of CVD at the end of follow‐up, incorporating all of
the covariates in the model as main effects. We estimate a model for
the full sample and separately for both split‐half samples. Standard
errors are computed using a bootstrap procedure with 2000 repeti-
tions.25 Following the modelling procedure, we test if the proportional
hazards assumption was violated.26
In nonweighted CTA, every subject has a weight of one and the
model identifies attributes that classify subjects with maximum accu-
racy. In contrast, for aweightedCTA survival model, theweight of every
subject is their follow‐up time (ie, the number of days of follow‐up), and
the model identifies attributes that classify subject‐days with maximum
accuracy. For example, a subject without CVD and lost to follow‐up
after 1000 days is coded as class = 0 (no CVD), weight = 1000; a subject
without CVD after maximum follow‐up (eg, 10 585 d) is coded as
class = 0, weight = 10 585; and a subject experiencing an event after
7919 days is coded as class = 1 (CVD), weight = 7919. The optimal
cutpoint is identified by iterating through every value of the attribute
and computing the weighted ESS (WESS), which is the mean weighted
sensitivity (ie, percent of correctly predicted subject‐days for each class)
across the classes, standardized to a 0 to 100% scale on which 0 repre-
sents the weighted discriminatory accuracy expected by chance and
100% represents perfect discrimination. By definition, the maximally
accurate predictive model uses the optimal cutpoint that achieves the
highest WESS, versus all other cutpoints. The optimal model is sub-
jected to a nonparametric permutation test to assess the statistical
validity of the cutpoint. Model reproducibility and cross‐generalizability
are assessed using a hold‐out (split‐half) method, which is one of several
possible cross‐validation techniques typically implemented as part of
the machine learning process.16,19
The present study demonstrates CTA‐based survival analysis—
which is implemented in 5 sequential steps. The first step uses
weighted CTA for each attribute considered individually, separately
for SH1 and SH2, to provide a “benchmark” for evaluating comparative
predictive performance of multivariable models using two or more
attributes.27 The second step obtains the descendant family of all
possible weighted CTA survival models using all available attributes,
separately for SH1 and SH2. Identical and parallel models identified
in SH1 and SH2 are considered reproducible and are hypothesized to
cross‐generalize to new independent random samples of subjects.
The third step evaluates intermodel agreement of outcome predictions
made by corresponding SH1 and SH2 survival models.19 The fourthstep involves a sensitivity analysis28 to assess the consistency of the
predictive accuracy yielded by the SH1 model used to classify the
SH2 sample—and by the SH2 model used to classify the SH1 sample
—over increasing annual follow‐up lengths: The first analysis omits
subjects with <1 year of follow‐up; the second analysis omits subjects
with <2 years of follow‐up, and so on, until either all follow‐up periods
have been evaluated or until the point at which a follow‐up period
yields samples that provide inadequate statistical power.19 The fifth
and final step evaluates whether computing new CTA survival models
for the SH1 and/or the SH2 samples improves WESS at strategic fol-
low‐up times identified in the sensitivity analysis. This is determined
by whether or not the WESS decreases beyond some empirically
defined level—indicating poor model fit. In such a circumstance, the
modelling process is repeated beginning with step 2.2.4 | Performance metrics
Several methods proposed to assess the accuracy of predictions
derived from survival models—including the concordance index,29,30
omnibus goodness‐of‐fit tests,31,32 and measures of explained varia-
tion versus explained randomness33—have been criticized on method-
ological grounds. Accordingly, we use the widely used Integrated Brier
Score (IBS)34 and introduce comparisons of WESS and of generated
survival curves.
First, we use the IBS to compare performance of the naïve
nonadjusted model, Cox regression with covariates, and weighted
CTA approaches, because its computation relies on 2 quantities avail-
able in every survival model—event status and predicted survival prob-
ability. For a given follow‐up time, the Brier score is calculated by
taking the squared difference between each individual's true survival
status and their predicted survival probability, weighted by their prob-
ability of censoring—and then averaged across all subjects. The
resulting score ranges between 0 and 1, with lower values indicating
lower prediction error. The IBS is an omnibus measure of the weighted
mean‐squared error (MSE) in predictive accuracy of the model across
all follow‐up times. For the present data, the IBS was estimated using
the riskRegression package in R35 truncating the maximum follow‐up
time at 10 590 days (29 y), because of the sparsity of events occurring
beyond that time.
Second, we perform pairwise comparisons between models on
estimated survival curves to determine whether they are discriminable
at any point along the follow‐up continuum. The Kaplan‐Meier (KM)
product‐limit estimator36 was used to estimate a survivor function
for the naïve (nonadjusted) model and each of the three‐strata EO‐
CTA survival model endpoints and both two‐strata GO‐CTA survival
model endpoints. A postestimation survival function was computed
following estimation of the Cox regression model with covariates.
Stata 14.1 (StataCorp, College Station, Texas) was used to estimate
the Cox regression model and generate all survival curves. To be con-
sistent with the 10‐year (3650 d) event horizon used for predicting
CVD in the Framingham project,2 we also estimated survival curves
for a 10‐year follow‐up period. Nonweighted GO‐CTA was used to
perform pairwise comparisons between the naïve model and each of
the 6 adjusted survival curves; and between the Cox regression model
with covariates and each of the 5 CTA survival model‐based curves.
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3.1 | Baseline characteristics, follow‐up length, split‐
half samples, and Cox regression results
Table 1 presents baseline characteristics and length of follow‐up of
study participants, by CVD outcome status and sample (ie, split‐half
or full), as well as the results of the Cox regression analysis. By the
end of the follow‐up period (11 688 d), approximately 46% of the
study population developed CVD; on average, these were older males
with higher baseline blood pressure, serum cholesterol level, and BMI.TABLE 1 Baseline characteristics and length of follow‐up of study participa
regression results
Variable Sample
No CVD
N Mean SD
SBP, mmHg SH1 1602 130.2 21.2
SH2 1624 129.8 21.4
Full 3226 130.0 21.3
DBP, mmHg SH1 1602 81.2 12.2
SH2 1624 80.9 12.3
Full 3226 81.0 12.2
SCL, mg/100 mL SH1 1586 222.9 43.0
SH2 1614 223.1 41.8
Full 3200 223.0 42.4
Age, years SH1 1602 45.4 8.5
SH2 1624 45.0 8.3
Full 3226 45.2 8.4
BMI, kg/m2 SH1 1601 25.2 4.0
SH2 1617 25.2 4.0
Full 3218 25.2 4.0
Male, % SH1 624 39.0
SH2 602 37.1
Full 1226 38.0
Follow‐up, days SH1 1602 9012.0 3395
SH2 1624 9041.0 3362
Full 3226 9027.0 3378
Notes: Cox regression values represent coefficients, with bootstrapped standar
pressure; SCL, serum cholesterol level; BMI, body mass index.
*P < .001.
TABLE 2 Weighted CTA models discriminating subjects with versus witho
Variable Split‐half
Cutpoint predicting
disease status Weighte
SBP, mmHg SH1 ≤145
SH2 ≤149
DBP, mmHg SH1 ≤99
SH2 ≤99
SCL, mg/100 mL SH1 ≤292
SH2 ≤276
Age, years SH1 ≤54
SH2 ≤58
BMI, kg/m2 SH1 ≤30.8
SH2 ≤34.1
Gender SH1 Male
SH2 Male
Notes: All estimates are weighted by follow‐up. For WESS, 0 = weighted ESS exp
of results is for analysis involving SH1, and the second row of results is for analy
the tabled threshold value (computed by the ODA algorithm) are predicted to be
than the tabled threshold are predicted to be from the disease group (coded as 1
DBP, diastolic blood pressure; SCL, serum cholesterol level; BMI, body mass indThe SH1 and SH2 samples were comparable on all baseline character-
istics, outcomes, and follow‐up times, as assessed by CTA: No statisti-
cally significant model emerged (all P > .05), indicating that SH1 and
SH2 could not be discriminated on the basis of these variables. In the
Cox regression analysis, all covariates were statistically significant
(P < .001) except diastolic blood pressure. All models (full, SH1, and
SH2) produced similar estimates, further demonstrating comparability
of the samples. Postestimation tests revealed that the proportional‐
hazards assumption was violated for gender. While beyond the scope
of the present study, in general, if the proportional‐hazards assumption
fails, then alternative modelling choices should be considered.37nts, by CVD outcome status and sample (full and by split‐half), and Cox
CVD Cox regression results
N Mean SD Coefficient SE
725 137.7 23.6 0.011* 0.003
748 139.9 25.6 0.009* 0.002
1473 138.8 24.7 0.010* 0.002
725 85.4 12.7 0.001 0.005
748 86.3 13.7 0.008 0.005
1,473 85.8 13.2 0.005 0.003
720 238.8 46.1 0.004* 0.001
746 240.8 47.8 0.006* 0.001
1466 239.8 46.9 0.005* 0.001
725 47.9 8.4 0.040* 0.005
748 47.9 8.3 0.043* 0.005
1473 47.9 8.4 0.041* 0.003
724 26.6 4.2 0.037* 0.009
748 26.5 4.0 0.030* 0.009
1,472 26.6 4.1 0.033* 0.007
417 57.5 0.779* 0.079
406 54.3 0.764* 0.079
823 55.9 0.771* 0.055
725 5957 3178
748 5937 3066
1473 5947 3121
d errors in parentheses. SBP, systolic blood pressure; DBP, diastolic blood
ut CVD, by variable (attribute) and split‐half
d sensitivity (CVD)
Weighted specificity
(No disease) WESS (Exact P<)
26.6 84.3 10.8 (.001)
24.2 87.2 11.4 (.001)
12.4 93.4 5.8 (.001)
15.0 94.6 9.6 (.001)
11.4 94.1 5.5 (.001)
16.6 90.9 7.5 (.001)
21.5 87.3 8.8 (.001)
9.2 95.0 4.2 (.004)
13.2 93.4 6.6 (.001)
4.4 98.0 2.4 (.023)
54.8 62.1 16.9 (.001)
51.6 63.9 15.5 (.001)
ected by chance, 100 = perfect prediction. For every attribute the first row
sis involving SH2. For all models subjects having values less than or equal to
from the no disease group (coded as 0), and subjects having values greater
). Exact P values are given for all WESS values. SBP, systolic blood pressure;
ex.
FIGURE 1 The three‐strata weighted CTA survival model 7 obtained
using SH1 (with probability of disease estimated for the SH2 sample),
for SH2 (with probability of disease estimated for the SH1 sample), and
for the full sample (with probability of disease estimated for the full
sample). CTA, classification tree analysis
LINDEN AND YARNOLD 13033.2 | Weighted CTA for attributes evaluated
individually (step 1)
Table 2 presents the results of applying weighted CTA to individual
attributes to predict subject CVD status, separately by split‐half sample.
All models yielded relatively weak WESS and were statistically signifi-
cant (age and body mass index effects for SH2 were only statistically
significant if evaluated using the “per‐comparison” P < .05 criterion18).
3.3 | Obtaining all possible weighted CTA models
separately for SH1 and SH2 and identifying the
identical and parallel models (step 2)
Table 3 presents all of the statistically valid CTA survival models
obtained for predicting CVD status, separately for SH1 and SH2. Two
models were retained. First, an identical two‐strata weighted GO‐CTA
model using gender as the only attribute (if gender = male then predict
disease; if gender = female then predict no disease) was identified as
model 8 for SH1 and SH2. This model estimated probability of disease
as 0.1787 or 0.1863 for females, and 0.3020 or 0.3019 for males, for
SH1 and SH2, respectively. Second, parallel weighted EO‐CTA models
were obtained as models 6 and 7—in which SH1 and SH2 models were
identical except for the systolic blood pressure (SBP) cutpoint value.
Model 6 used gender as the root attribute and then SBP, and model 7
used SBP as the root attribute and then gender. Thesemodels had iden-
tical WESS within complementary split‐half samples, but model 7 was
selected as the three‐strata model because it had the largest minimum
strata N, thus providing greatest statistical power.19 Figure 1 illustrates
model 7 for SH1 and SH2 and summarizes hold‐out validity classifica-
tion results obtained by applying the SH1 model to the SH2 sample,
and vice versa. Consistent with findings for model 8, predicted out-
comes for model 7 are highly consistent between SH1 and SH2.
3.4 | Evaluating intermodel agreement of outcome
predictions made by corresponding SH1 and SH2
survival models (step 3)
Agreement of outcome predictions made by models 7 and 8 was
assessed for the full sample. Cross‐classifying predicted disease statusTABLE 3 All weighted CTA survival models predicting CVD identified for
SH1
Model Strata WESS Efficiency D Smallest strata N
1 6 25.38 4.23 17.64 42
2 5 24.28 4.86 15.59 80
3 5 22.95 4.59 16.79 114
4 4 22.73 5.68 13.60 217
5 4 22.65 5.66 13.66 222
6 3 22.57 7.52 10.29 339
7 3 22.57 7.52 10.29 538
8 2 16.91 8.46 9.83 1,041
Notes: Strata is the number of model endpoints (terminal nodes); WESS measure
chance; 100 = perfect accuracy); efficiency is WESS divided by strata—a measu
distance statistic D indicates the number of additional effects with equivalent W
accuracy and maximum possible parsimony for the application; and smallest stra
jects among all endpoints in the model.19,46of subjects using model 8 (which was identical for SH1 and SH2)
yielded 2650 subjects similarly classified as having no disease, and
2049 subjects similarly classified as having disease—revealing perfect
congruence (ESS = 100). In contrast, model 7 differed for SH1 and
SH2 (ie, the SBP threshold value was 145.5 versus 149.5 mmHG,
respectively). Cross‐classifying predicted disease status of subjects
obtained using SH1‐ and SH2‐based model 7 yielded 1962 of 2055
subjects similarly classified as having no disease, and 2644 subjects
similarly classified as having disease—indicating near‐perfect agree-
ment: ESS = 95.5 for SH1 model and ESS = 96.6 for SH2 model.3.5 | Sensitivity analysis assessing model validity for
increasingly longer follow‐ups (step 4)
Sensitivity analysis was conducted to assess stationarity of the
predictive accuracy (WESS) for models 7 and 8 for SH1 and SH2, over
increasing follow‐up periods. In each analysis, the WESS for SH1 waseach split‐half training sample
SH2
Model Strata WESS Efficiency D Smallest strata N
1 8 27.03 3.38 21.60 50
2 7 25.59 3.66 20.35 52
3 6 25.13 4.12 17.88 79
4 4 24.74 6.18 12.17 225
5 4 22.95 5.74 13.43 260
6 3 22.77 7.59 10.18 299
7 3 22.77 7.59 10.18 464
8 2 15.53 7.76 10.88 1008
s normed weighted predictive accuracy (0 = weighted accuracy expected by
re of the magnitude of normed accuracy yielded per model endpoint; the
ESS that are needed to obtain a theoretically ideal model yielding perfect
ta N is the number of subjects in the endpoint representing the fewest sub-
1304 LINDEN AND YARNOLDassessed by applying the SH1 model to classify the SH2 (“hold‐out”)
sample, and vice versa. Model WESS was computed using data from
subsamples representing increasing annual follow‐up periods—ranging
from more than 1 year to more than 28 years (models for longer
periods failed statistical power criteria). Table A.1 presents the findings
of the sensitivity analysis, which indicates that models 7 and 8 each
have stable, comparable hold‐out validity WESS between split‐half
samples across time.3.6 | Evaluating new (recalibrated) CTA survival
models for the SH1 and SH2 samples at follow‐up
times indicated in sensitivity analysis (step 5)
Three attempted model recalibration analyses were indicated by the
sensitivity analysis. The first attempted recalibration occurred at
>12 years follow‐up—the first time model 8 had a WESS value 10%
lower than obtained in initial (all data) analysis. For models 7 and 8,
for SH1 and SH2, restricting follow‐up to >12 years yielded the identi-
cal models 7 and 8. Identical results were also obtained for the second
recalibration analysis at >13 years follow‐up—the first time WESS for
model 7 was 10% lower than the initial value. And identical results
were obtained for the final recalibration analysis at >21 years follow‐
up—the first time WESS for models 7 and 8 was 15% lower than the
initial value. In summary, sensitivity and model recalibration analyses
confirmed findings consistent with the total sample analysis, over the
range of follow‐up periods studied.3.7 | Comparing naïve, Cox regression, and CTA
survival model survival curves
Figure 2 illustrates the estimated survival curves for all models derived
in the present study. These include the CTA two‐strata gender model
obtained for SH1 and SH2, the CTA three‐strata model obtained for
SH1 (using a SBP cutpoint of 145.5 mmHg, which yielded the greatest
ESS for SH1 and for the full sample), the naïve (unadjusted) Kaplan‐
Meier estimate, and the covariate‐adjusted Cox regression. As shown,
the highest survival rate was predicted by the three‐strata CTA model
with the rule SBP ≤ 145.5 mmHg and female. Conversely, the lowestsurvival rate was predicted by the three‐strata CTA model with the
rule SBP > 145.5 mmHg. Females (from the two‐strata CTA model)
had the second highest predicted survival, while males (also from the
two‐strata CTA model) had the second lowest predicted survival rates.
The adjusted Cox regression model produced survival rates similar to
the naïve (Kaplan‐Meier) estimate, and both were positioned in the
middle of the range of models. Thus, the Cox model best predicts aver-
age (omnibus) incidence of the outcome across follow‐up whereas the
CTA models best predict either relatively high, or low, incidence of the
outcome over time.
Two methods were used to compare the prediction error/accu-
racy between these survival modelling approaches. First, the IBSs for
predicted survival estimates for the 7 models are presented in
Table A.2. The naïve survival estimate, which serves as a general
benchmark, produced a weighted mean‐squared prediction error of
0.122, while the adjusted Cox regression had a slightly lower level of
0.104. Different CTA survival model strata produced varying levels of
prediction error. For example, the overall best IBS score (0.069) was
achieved by the stratum of the three‐strata model in which survival
was predicted by SBP ≤ 145.5 mmHg and gender = female. Con-
versely, in the same model, the stratum in which survival was predicted
simply as SBP > 145.5 mmHg produced the highest weighted mean‐
squared prediction error (0.168). In the two‐strata model, predicting
survival for females elicited less prediction error than that for males
(0.096 vs 0.148, respectively). Overall, the greater the predicted inci-
dence of CVD for a model endpoint (all incidence estimates were
<50%), the greater the heterogeneity in class status of subjects in the
model endpoint—and therefore the greater the IBS score.
In the second approach used to compare survival estimates, the
first of 2 sets of analyses compared naïve (nonadjusted) model (ie,
actual) 10‐year disease‐free survival versus 10‐year disease‐free sur-
vival estimated using each adjusted model (data available from
authors). Ten‐year disease‐free survival predicted by the Cox model
(relatively weak ESS = 20.9), and by the leftmost endpoints of the
two‐strata (moderate ESS = 28.0) and the three‐strata (relatively
strong ESS = 51.9) CTA survival models, was significantly greater than
unadjusted 10‐year survival. Conversely, 10‐year disease‐free survival
predicted by the rightmost endpoint of the two‐strata CTA survivalFIGURE 2 Estimated survival curves for all
models in the present study. Ordering of
models listed in the legend corresponds to
ordering of the curves, from top to bottom
LINDEN AND YARNOLD 1305model (moderate ESS = 27.4), and by the middle (relatively weak
ESS = 14.6) and rightmost (moderate ESS = 38.8) endpoint of the
three‐strata CTA survival model, was significantly lower than unad-
justed 10‐year survival.
The second set of comparative analyses in the second approach,
examined the predicted 10‐year survival for the Cox model versus for
the 5 (one for eachendpoint) two‐ and three‐strataCTA survivalmodels.
10‐year disease‐free survival predicted by the leftmost endpoints of the
two‐strata (relatively weak ESS = 9.3) and three‐strata (moderate
ESS=34.0)CTAsurvivalmodelswas significantly greater thanestimated
10‐year survival by the Cox model. Conversely, 10‐year disease‐free
survival predicted by the rightmost endpoint of the two‐strata CTA sur-
vival model (moderate ESS = 39.4), and by the middle (moderate
ESS = 32.1) and right‐most (relatively strong ESS = 56.2) endpoint of
the three‐strata CTA survival model, was significantly lower than esti-
mated 10‐year survival by the Cox model. In summary, the first set of
analyses reveal that all six of the adjusted survivalmodels generated sur-
vival curves that were significantly different than the unadjusted (naïve)
KM curve, when compared over 10 years of follow‐up, and the second
set of analyses reveal that all five of the CTA‐based survival curveswere
significantly different (and thus more accurate in predicting either posi-
tive or negative CVD status) than the Cox regression survival curve,
when compared over 10 years of follow‐up.4 | DISCUSSION
Machine learning techniques are increasingly being used in health care
research for applications such as improving diagnostic accuracy,
identifying high‐risk patients, and extracting concepts in unstructured
data.38 In this paper, we introduce CTA as an appealing machine
learning alternative for modelling censored data that offers several
important advantages over the commonly used Cox regression.
First, investigators using regression‐based models have little
guidance in their model‐building process. For example, some studies
estimate models in which the variable selection process includes only
main effects, others estimate completely saturated models (including
all possible interactions, and squared and cubed terms), and others use
automated forward or backward stepwise procedures to select vari-
ables for model inclusion. Such heterogeneous approaches to estima-
tion are likely to produce misspecified or suboptimally fit models.
Indeed, postestimation tests following Cox regression in the present
study indicated that the proportional‐hazards assumption was violated
for gender.Moreover, the estimated disease‐free survival curve derived
from the Cox model followed a similar trajectory to that of the unad-
justed Kaplan‐Meier estimate, suggesting that the more complex Cox
model offered little additional ability to predict disease‐free survival
probability as compared with a simple model. A unique advantage of
GO‐CTA survival analysis in this regard is that all statistically valid,
reproducible, longitudinally consistent, and generalizable CTA models
existing for a given sample are identified by an algorithm‐driven process,
eliminating concerns of model misspecification.39
Second, among CTA's most salient features is the generation of
simple decision rules to aid both clinicians and researchers to identify
subjects exhibiting specific characteristics that place them at higher orlower risk for realizing the outcome. When supplemented with their
respective survival curves, such decision rules become even more
compelling. For example, in reviewing Figure 1, we see that the
stratum with the lowest predicted probability of disease in the full
model (0.6592) has the rule SBP > 145.5 mmHg, which coincides with
the lowest estimated disease‐free survival function presented in
Figure 2. Taken together, a clinician is given a simple, maximally
accurate rule for identifying individuals with a modifiable risk,
augmented by 2 complementary estimates of disease‐free survival.
Conversely, regression‐based survival models offer no such interpret-
able formulae or visual displays of the final model.
Third, a measure of weighted MSE in predicted survival, IBS scores
increased systematically with decreasing disease‐free survival curves
(Figure 2). We attribute this relationship to variability in the estimated
survival curves, which is maximized when predicted probability of sur-
vival is 0.50. The stratum with the highest overall survival estimate
(SBP ≤ 145.5 mmHg and female) had the lowest variability and MSE,
while thestratumwith the lowestpredictedsurvival (SBP>145.5mmHg)
had the highest variability and MSE. Therefore, an investigator can feel
confident that parsimonious CTA‐based stratum‐specific decision rules
predicting highest survival rates produce survival predictions with an
associated weighted MSE that is lower than that of more complex Cox
models. However, we argue that WESS is a more appropriate measure
of a model's predictive accuracy specifically because it is insensitive to
the variability in the predicted outcome.
Additionally, we found that Cox regression produced an estimated
disease‐free survival curve that was statistically different than those of
all CTA‐based model strata, while converging with the Kaplan Meier
estimate over a very long follow‐up—possibly indicative of regression
to the mean effects.19,40 In contrast, 2 easily discriminated (P < .001)
CTA models that predicted lower CVD incidence than the Cox model
had comparatively flatter trajectories across follow‐up, and 3 easily
discriminated (P's < .001) CTA models predicting higher CVD incidence
than the Cox model had comparatively accelerated trajectories over
follow‐up (Figure 2). As is clearly seen, the Cox model best predicts
average (omnibus) incidence of the outcome across follow‐up, whereas
CTA survival models best predict either relatively high, or low, inci-
dence of the outcome across follow‐up.
Finally, while this paper has focused on the application of CTA
to censored data for developing maximally accurate prognostic
models, a logical extension of these methods lies in the evaluation
of nonrandomized intervention studies with censored outcomes
(eg, targeting poor health behaviours that may cause disease or
death). Linden and Yarnold39 introduced a CTA‐based approach to
generating propensity score weights. Propensity scoring techniques
are in a family of methods that explicitly model treatment assign-
ment to estimate treatment effects in nonrandomized studies.41,42
To estimate treatment effects with censored data using CTA,
propensity score weights would be first generated as described in
Linden and Yarnold,39 and then multiplied by follow‐up time. The
GO‐CTA survival analysis would then be conducted as described herein.
The primary limitation of the CTA framework for developing prog-
nostic models with censored data—as is the case with every analytic
approach used for this purpose—is that models are generated using
only the available data. No matter how sophisticated the algorithm,
1306 LINDEN AND YARNOLDimportant unobservable factors such as unmeasured motivation to
change health behaviours may limit the ability of any model to
accurately predict the outcome.43,44 Another general limitation affect-
ing all prognostic modelling approaches is that the predictive values of
the model are highly sensitive to the prevalence rate of the observed
outcome in that population evaluated.45 More specifically, in a
population where nearly everyone is disease‐free, it would be much
easier to predict a person's probability of being disease‐free, and much
harder to predict who will develop the disease.5 | CONCLUSION
In summary, this paper introduced a novel machine learning framework
for modelling censored data. This framework offers many advantages
over broadly used Cox regression, such as explicit maximization
of accuracy, parsimony, sensitivity, statistical robustness, and
transparency. Therefore, researchers interested in accurate prognoses
and clear decision rules should consider developing models using the
CTA‐survival framework.
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1308 LINDEN AND YARNOLDAPPENDIX ATable A2. Integrated Brier Scores (IBS) for each model in the current study
Model IBS
Naïve Kaplan Meir (w/o covariates) 0.122
Cox regression with covariates 0.104
Model 7a: SBP ≤ 145.5 and gender = female 0.069
Model 7b: SBP ≤ 145.5 and gender = male 0.135
Model 7c: SBP ≥ 145.5 0.168
Model 8a: Gender = Female 0.096
Model 8b: Gender = Male 0.148
Table A1. Sensitivity analysis applying CTA training models 7 and 8 to indepen
Training
Sample Model 7, SH1 Model 7, SH2
Test Sample
Model 7, SH2 Model 7, SH1
Minimum
Follow‐up
Wtd
Sensitivity
Wtd
Specificity WESS
Wtd
Sensitivity
Wtd
Specificity W
Full sample,
year
69.1 52.5 21.6 68.4 52.7
>1 69.1 52.5 21.6 68.4 52.7
>2 69.1 52.5 21.6 68.4 52.8
>3 69.0 52.5 21.5 68.3 52.8
>4 68.9 52.5 21.4 68.2 52.8
>5 68.9 52.5 21.4 68.0 52.8
>6 68.7 52.6 21.3 67.8 52.9
>7 68.6 52.7 21.3 67.6 52.9
>8 68.4 52.7 21.1 67.4 53.0
>9 68.2 52.7 20.9 67.1 53.1
>10 68.1 52.8 20.9 66.8 53.2
>11 67.8 52.8 20.6 66.2 53.1
>12 67.6 53.0 20.6 65.8 53.3
>13 67.5 53.1 20.6 65.6 53.4
>14 66.9 53.1 20.0 65.2 53.5
>15 66.7 53.1 19.8 65.4 53.7
>16 66.3 53.4 19.7 64.9 54.0
>17 65.6 53.6 19.2 64.8 54.0
>18 65.0 53.9 18.9 64.3 54.3
>19 65.4 54.0 19.4 64.4 54.3
>20 64.7 54.1 18.8 63.8 54.6
>21 63.2 54.2 17.3 63.4 54.9
>22 62.6 54.4 17.0 64.5 55.1
>23 62.3 54.9 17.2 65.0 55.5
>24 65.0 55.3 20.3 64.9 55.7
>25 65.6 55.5 20.9 65.6 55.9
>26 65.1 55.9 21.0 64.1 56.5
>27 68.7 56.4 25.1 62.6 57.0
>28 69.6 56.4 25.9 63.4 57.3
Notes: Tabled values were obtained by applying the indicated training model to
samples with an insufficient number of class = 1 (positive CVD outcome) subjedent test (hold‐out validity) samples
Model 8, SH1 Model 8, SH2
Model 8, SH2 Model 8, SH1
ESS
Wtd
Sensitivity
Wtd
Specificity WESS
Wtd
Sensitivity
Wtd
Specificity WESS
21.2 51.6 63.9 15.5 54.8 62.1 16.9
21.2 51.6 63.9 15.5 54.8 62.1 16.9
21.2 51.6 63.9 15.5 54.8 62.1 16.9
21.1 51.5 63.9 15.4 54.7 62.2 16.9
21.0 51.5 63.9 15.4 54.6 62.1 16.7
20.8 51.4 63.9 15.3 54.6 62.2 16.8
20.6 51.3 63.9 15.2 54.5 62.2 16.7
20.5 51.2 64.0 15.2 54.4 62.2 16.6
20.3 51.1 64.0 15.1 54.1 62.2 16.3
20.3 51.0 64.0 15.0 53.8 62.3 16.1
19.9 51.0 64.1 15.1 53.7 62.3 15.9
19.4 51.3 64.1 15.3 53.3 62.2 15.5
19.1 51.1 64.1 15.1 52.8 62.2 15.0
19.0 51.1 64.1 15.2 52.6 62.3 14.8
18.7 50.4 64.1 14.5 53.0 62.3 15.3
19.1 50.6 64.1 14.7 53.2 62.3 15.5
19.0 50.9 64.1 15.0 53.4 62.5 15.8
18.8 50.6 64.2 14.7 53.2 62.5 15.8
18.6 50.1 64.3 14.4 53.3 62.6 15.8
18.7 50.6 64.4 14.9 53.6 62.5 16.1
18.4 49.2 64.3 13.5 52.6 62.7 15.2
18.3 47.3 64.4 11.8 52.6 62.8 15.4
19.6 46.2 64.6 10.8 53.0 63.1 16.1
20.5 46.1 65.0 11.0 53.4 63.1 16.6
20.6 47.3 65.4 12.7 53.3 63.2 16.5
21.6 48.9 65.5 14.3 54.1 63.1 17.2
20.6 53.3 63.3 16.5 48.7 65.7 14.4
19.6 53.0 65.7 18.7 51.8 63.2 15.1
20.7 55.0 65.6 20.7 51.8 63.4 15.1
the indicated validity sample. Minimum follow‐up values >29 y produced
cts to satisfy the minimum statistical power criterion.19
